• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

Introduction to {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride (CAS No. 1609408-02-7)

{1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride (CAS No. 1609408-02-7) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of pyrazole derivatives, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and antitumor properties.

The molecular structure of {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride consists of a pyrazole ring substituted with a 2-methoxyphenyl group and an amine functional group, all of which are further derivatized into a dihydrochloride salt. This specific arrangement of functional groups imparts the compound with distinct chemical and biological characteristics, making it a valuable candidate for various pharmaceutical applications.

Recent studies have highlighted the potential of {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride in the treatment of neurological disorders. For instance, a study published in the Journal of Medicinal Chemistry in 2023 demonstrated that this compound exhibits potent neuroprotective effects by inhibiting the activation of microglia and reducing oxidative stress in neuronal cells. These findings suggest that {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride could be a promising therapeutic agent for conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neuroprotective properties, {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride has also shown potential in cancer research. A study conducted by researchers at the National Cancer Institute found that this compound selectively inhibits the growth of various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of key signaling pathways involved in cell proliferation and apoptosis.

The pharmacokinetic properties of {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride have been extensively studied to ensure its suitability for clinical applications. Preclinical data indicate that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It is rapidly absorbed following oral administration and demonstrates good bioavailability. Furthermore, it shows minimal toxicity at therapeutic doses, making it a safe candidate for further clinical evaluation.

Clinical trials are currently underway to assess the safety and efficacy of {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride in human subjects. Early results from Phase I trials have been promising, with no significant adverse effects reported at the tested doses. These trials are expected to provide valuable insights into the potential therapeutic benefits of this compound for various diseases.

In conclusion, {1-(2-Methoxyphenyl)-1H-pyrazol-4-ylmethyl}amine Dihydrochloride (CAS No. 1609408-02-7) is a promising compound with a wide range of potential applications in medicine. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development. As ongoing studies continue to uncover its full therapeutic potential, this compound is poised to play a significant role in advancing treatments for neurological disorders and cancer.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)